VERTEX PHARMACEUTICALS INC / MA Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 9 rows in 2025. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2025-12-04: Reporting owner LEIDEN JEFFREY M; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2025-12-03: Reporting owner LEIDEN JEFFREY M; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2025-11-14: Reporting owner LEIDEN JEFFREY M; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2025-11-14: Reporting owner LEIDEN JEFFREY M; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-12-04 | LEIDEN JEFFREY M Director, Officer (Executive Chairman) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1 0 owned after | $91.05 exercise price | $457.36 | 2025-12-05 |
| 2025-12-03 | LEIDEN JEFFREY M Director, Officer (Executive Chairman) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −63,781 0 owned after | $86.52 exercise price | $463.13 | 2025-12-05 |
| 2025-11-14 | LEIDEN JEFFREY M Director, Officer (Executive Chairman) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,835 1 owned after | $91.05 exercise price | $437.15 | 2025-11-17 |
| 2025-11-14 | LEIDEN JEFFREY M Director, Officer (Executive Chairman) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −39,769 63,781 owned after | $86.52 exercise price | $437.15 | 2025-11-17 |
| 2025-11-13 | LEIDEN JEFFREY M Director, Officer (Executive Chairman) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −19,688 13,836 owned after | $91.05 exercise price | $434.52 | 2025-11-17 |
| 2025-05-01 | Thornberry Nancy Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,199 1,199 owned after | $502.97 exercise price | $498.86 | 2025-05-05 |
| 2025-05-01 | SACHS BRUCE I Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +2,398 2,398 owned after | $502.97 exercise price | $498.86 | 2025-05-05 |
| 2025-05-01 | Lagarde Michel Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +2,398 2,398 owned after | $502.97 exercise price | $498.86 | 2025-05-05 |
| 2025-05-01 | Garber Alan M Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,199 1,199 owned after | $502.97 exercise price | $498.86 | 2025-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |